pMP71-tCD19-LLO-SIINFEKL
(Plasmid
#174598)
-
Purposeexpresses the extracellular and transmembrane domain of murine CD19 with a C terminal fusion of the LLO190 and SIINFEKL epitopes
-
Depositing Lab
-
Sequence Information
Ordering
This material is available to academics and nonprofits only.
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 174598 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 | |
Backbone
-
Vector backbonemp71
-
Vector typeMammalian Expression
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert namemembrane bound CD19, LLO antigen, SIINFEKL (ovalbumin) antigen
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
How to cite this plasmid
( Back to top)
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pMP71-tCD19-LLO-SIINFEKL was a gift from Stanley Riddell (Addgene plasmid # 174598 ; http://n2t.net/addgene:174598 ; RRID:Addgene_174598) -
For your References section:
A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells. Veatch JR, Singhi N, Srivastava S, Szeto JL, Jesernig B, Stull SM, Fitzgibbon M, Sarvothama M, Yechan-Gunja S, James SE, Riddell SR. J Clin Invest. 2021 Aug 16;131(16):e144195. doi: 10.1172/JCI144195. 10.1172/JCI144195 PubMed 34396986
